Mechanochemistry Can Reduce Life Cycle Environmental Impacts of Manufacturing Active Pharmaceutical Ingredients

The scale-up of mechanochemical methods could play a transformative role in making manufacturing processes in the pharmaceutical industry greener by eliminating solvent use and recovery. Combined with energy-efficient continuous processing that consolidates reaction steps, mechanochemistry's environ-mental and economic benefits may translate across product supply chains. Here, we evaluate numerous sustainability and green chemistry metrics for producing nitrofurantoin, an active pharmaceutical ingredient (API), via mechanochemical continuous twin-screw extrusion (TSE) and conventional solvent-batch synthesis methods. We find a significant reduction in all metrics for TSE including energy, climate change, and human and ecological health, as well as cost due to reducing excess reactant consumption and eliminating solvents while maintaining high product selectivity. In addition, replacing the direct energy source to drive the chemical reaction from mostly thermal to electrical sources does not increase the net life cycle energy consumed to produce functionally equivalent API. We conclude that mechanochemical synthesis via TSE holds multiple sustainability benefits for manufacturing APIs and potentially other chemical products.

Automated summary

The scale-up of mechanochemical methods has the potential to make manufacturing processes in the pharmaceutical industry greener by eliminating the use of solvents. The study evaluates the sustainability and green chemistry metrics for producing nitrofurantoin via mechanochemical continuous twin-screw extrusion and conventional solvent-batch synthesis methods. The results show significant reductions in energy, climate change, and cost for the mechanochemical method, while maintaining high product selectivity.